-
Randomized Controlled Trial Multicenter Study
Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Results After Repeat Treatment.
- Leslie Baumann, Rhoda S Narins, Kenneth Beer, Arthur Swift, Kimberly J Butterwick, Julius Few, Adrienne Drinkwater, and Diane K Murphy.
- *Baumann Cosmetic and Research Institute, Miami, Florida; †Dermatology Surgery and Laser Center, New York, New York; ‡Beer Cosmetic, Surgical and General Dermatology, West Palm Beach and Jupiter, Florida; §The Westmount Institute of Plastic Surgery, Montreal, QC, Canada; ‖Cosmetic Laser Dermatology, San Diego, California; ¶Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, The Few Institute for Aesthetic Plastic Surgery, Chicago, Illinois; #Suffield, Connecticut; **Allergan plc, Irvine, California.
- Dermatol Surg. 2015 Dec 1; 41 Suppl 1: S284-92.
BackgroundJuvéderm Voluma XC (VYC-20L; hyaluronic acid gel) is approved in the United States for correction of age-related midface volume deficit (MVD).ObjectiveAssess safety and effectiveness of VYC-20L after repeat treatment.MethodsSubjects with MVD underwent optional repeat treatment 12 to 24 months after initial treatment if correction was lost or at 24 months regardless of loss of correction (n = 167). Investigators rated outcomes on the Mid-Face Volume Deficit Scale (MFVDS) and the Global Aesthetic Improvement Scale (GAIS). Subject-rated outcomes were the GAIS, overall satisfaction with facial appearance, achievement of treatment goal, and Self-Perception of Age questionnaire. Subjects recorded treatment-site responses in 30-day diaries.ResultsMean injection volume for repeat treatment (3.13 mL) was approximately half the mean total injection volume for initial/touch-up treatment (6.8 mL). After repeat treatment, effectiveness was demonstrated on all investigator-rated and subject-rated measures, consistent with results observed after initial treatment. The percentage of subjects improving by ≥1 point on the MFVDS was 82.8% and 91.1% at 6 and 12 months after repeat treatment, respectively. The incidence, severity, and duration of common treatment-site responses were lower after repeat versus initial treatment.ConclusionRepeat treatment with VYC-20L was well tolerated and resulted in high levels of effectiveness and subject satisfaction.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.